Trial · NCT07391878
Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.
NCT07391878, Phase 2, Not yet recruiting, Trigone Pharma Ltd.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder. Trials, record NCT07391878. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07391878
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.
- NCT number
- NCT07391878
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Trigone Pharma Ltd.
- Conditions
- Overactive Bladder (OAB)
- Interventions
- TRG-200 KIT
- First posted
- 2026-02-06
- Last updated
- 2026-02-06
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Average Number of Micturitions per 24 Hours | Baseline to Week 12 | Change from baseline in the average number of micturitions per 24 hours, as recorded in a 3-day patient voiding diary. |
| Primary | Change From Baseline in Average Number of Urgency Episodes per 24 Hours | Baseline to Week 12 | Change from baseline in the average number of urgency episodes (defined as a sudden and compelling desire to void) per 24 hours, based on the 3-day patient voiding diary. |
| Primary | Change From Baseline in Average Number of Urgency Urinary Incontinence (UUI) Episodes per 24 Hours | Baseline to Week 12 | Change from baseline in the average number of urgency urinary incontinence (UUI) episodes per 24 hours, as recorded in the 3-day patient voiding diary. |
| Secondary | Proportion of Participants With ≥50% Reduction in Micturitions per 24 Hours | Baseline to Week 12 | Proportion of participants achieving at least a 50% reduction from baseline in the average number of micturitions per 24 hours, based on the 3-day patient voiding diary. |
| Secondary | Proportion of Participants With ≥50% Reduction in Urgency Episodes per 24 Hours | Baseline to Week 12 | Proportion of participants achieving at least a 50% reduction from baseline in the average number of urgency episodes per 24 hours, based on the 3-day patient voiding diary. |
| Secondary | Proportion of Participants With ≥50% Reduction in Urgency Urinary Incontinence (UUI) Episodes | Baseline to Week 12 | Proportion of participants achieving at least a 50% reduction from baseline in the average number of urgency urinary incontinence (UUI) episodes per 24 hours. |
| Secondary | Change From Baseline in Nocturnal Voids per Night | Baseline to Week 12 | Change from baseline in the average number of nocturnal voids per night, as recorded in the 3-day patient voiding diary. |
| Secondary | Change From Baseline in Average Voided Volume | Baseline to Week 12 | Change from baseline in average voided volume (mL), measured using a calibrated measuring device and recorded in the patient voiding diary. |
| Secondary | Change From Baseline in Quality of Life Score | Baseline to Week 12 | Change from baseline to Week 12 in quality of life related to lower urinary tract symptoms, assessed using the LUTN questionnaire total score. The LUTN questionnaire total score ranges from 0 to 100, with higher scores indicating greater symptom burden and poorer quality of life, and lower scores indicating improvement. The outcome measure will be reported as the mean change from baseline. |
| Secondary | Improvement in Patient Perception of Bladder Condition (PPBC) | Baseline to Week 12 | Proportion of participants achieving an improvement of at least 1 point on the 6-point Patient Perception of Bladder Condition (PPBC) scale. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07391878
GET https://conductscience.org/api/trials/v1/NCT07391878/registered